一种可注射的皮下结肠特异性免疫,用于治疗性结肠炎
Kin Man Au1, Justin E Wilson2,3, Jenny P-Y Ting2,3
1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. kinman.au@utsouthwestern.edu.
Nature biomedical engineering
|December 4, 2023
概括
一个新的生物工程利基促进肠道免疫耐受性,用于性结肠炎 (UC) 治疗. 这种结肠特异性疗法减少炎症,有助于上皮质修复,并预防大肠炎相关的癌症在小鼠模型.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 生物材料科学 生物材料科学
背景情况:
- 性结肠炎 (UC) 是一种慢性自身炎症性疾病,通常用全身免疫抑制剂治疗.
- 目前的治疗方法存在风险,可能无法完全消除炎症或相关并发症.
- 需要有针对性的疗法来诱导结肠内的局部免疫耐受性.
研究的目的:
- 开发和评估一个结肠特异性免疫抑制利基治疗性结肠炎.
- 调查这种利基产生的肠道免疫耐受性的机制.
- 评估利基市场在预防大肠炎相关并发症,包括癌症方面的有效性.
主要方法:
- 使用结肠上皮细胞,脱细胞化细胞外基质和功能化纳米纤维创建一个生物工程利基.
- 将编程死亡连接体1,CD86,一个TGF-β1模仿和莱夫卢诺米德纳入利基.
- 在三种已确诊的性结肠炎的小鼠模型中,以皮下注射利基.
- 免疫细胞透,T细胞无能,巨细胞两极分化,上皮恢复和癌症发展的分析.
主要成果:
- 生物工程领域成功诱导了肠道免疫耐受性,并减少了胃肠道下部的炎症.
- 这种利基触发了自动反应性T细胞无能性,并通过多种免疫抑制途径两极化了亲炎性巨细胞.
- 它阻止了免疫细胞透到结肠自身膜中,促进了上皮损伤的恢复.
- 该治疗还可以预防结肠炎相关的结肠直肠癌,并解决与免疫相关的结肠炎.
结论:
- 通过皮下注射,结肠特定的生物工程利基可以有效地治疗小鼠模型中的性结肠炎.
- 这种方法通过调节免疫细胞反应和促进组织修复来建立局部肠道免疫耐受性.
- 开发的利基显示了预防性结肠炎的严重并发症的潜力,包括癌症和药物诱导的结肠炎.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Inflammatory Bowel Disease V: Surgical Management
148
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
148


